Consumer medicine information

Ibilex

Cefalexin

BRAND INFORMATION

Brand name

Ibilex

Active ingredient

Cefalexin

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Ibilex.

SUMMARY CMI

IBILEX®

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using IBILEX?

IBILEX contains the active ingredient cefalexin monohydrate. IBILEX is used to treat infections caused by bacteria in different parts of the body, including infections of the respiratory tract (throat, tonsils, chest and lungs), nose (sinusitis), ears (otitis media), skin and soft tissue, kidneys and bladder (urinary tract). For more information, see Section 1. Why am I using IBILEX? in the full CMI.

2. What should I know before I use IBILEX?

Do not use if you have ever had an allergic reaction to cefalexin monohydrate, penicillin, other cephalosporins, or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I use IBILEX? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with IBILEX and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use IBILEX?

  • Follow all directions give to you by your doctor or pharmacist.
  • Your doctor will tell you how much and how often you should take IBILEX.

More instructions can be found in Section 4. How do I use IBILEX? in the full CMI.

5. What should I know while using IBILEX?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are using IBILEX.
  • Tell your doctor if the symptoms of your infection do not improve within a few days or if they become worse.
  • Tell your doctor if you become pregnant while taking IBILEX.
Things you should not do
  • Do not stop using this medicine suddenly or change the dosage unless your doctor tells you to.
  • Do not take IBILEX to treat any other complaints unless your doctor tells you to.
  • Do not give your medicine to anyone else, even if they have the same condition as you.
Driving or using machines
  • IBILEX may cause dizziness or drowsiness in some people.
  • Be careful driving or operating machinery until you know how IBILEX affects you.
  • Children should be careful when riding bicycles or climbing trees.
Looking after your medicine
  • IBILEX capsules: store below 30°C.
  • IBILEX suspension: store between 2-8°C. Do not freeze. Shake well before use and discard after 14 days.

For more information, see Section 5. What should I know while using IBILEX? in the full CMI.

6. Are there any side effects?

Common side effects include: sore or white mouth or tongue, sore and itchy vagina and/or discharge, diarrhoea, nausea, vomiting, dizziness, unusual tiredness/ weakness, abdominal pain, headache. Serious side effects include severe body rash, swelling of face, lips, mouth, tongue or throat, fever, swelling of the joints, yellowing of the skin or eyes, joint pain, confusion and hallucinations, seizure potential, bleeding or bruising more easily than normal, severe stomach cramps or pain, severe, watery or bloody diarrhoea. For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI



FULL CMI

IBILEX®

Active ingredient: cefalexin monohydrate


Consumer Medicine Information (CMI)

This leaflet provides important information about using IBILEX. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using IBILEX.

Where to find information in this leaflet:

1. Why am I using IBILEX?
2. What should I know before I use IBILEX?
3. What if I am taking other medicines?
4. How do I use IBILEX?
5. What should I know while using IBILEX?
6. Are there any side effects?
7. Product details

1. Why am I using IBILEX?

IBILEX contains the active ingredient cefalexin monohydrate. IBILEX is an antibiotic that belongs to a group of medicines called cephalosporins. These medicines work by killing the bacteria that are causing your infection.

IBILEX is used to treat infections caused by bacteria in different parts of the body, including infections of the:

  • respiratory tract (throat, tonsils, chest and lungs)
  • nose (sinusitis)
  • ears (otitis media)
  • skin and soft tissue
  • kidneys and bladder (urinary tract).

Ask your doctor or pharmacist if you have any questions about why IBILEX has been prescribed for you.

Your doctor may have prescribed IBILEX for another reason.

IBILEX will not work against infections caused by viruses, such as colds or flu.

IBILEX is available only with a doctor's prescription. There is no evidence that IBILEX is addictive.

2. What should I know before I use IBILEX?

Warnings

Do not use IBILEX if:

  • you are allergic to cefalexin monohydrate, penicillin, other cephalosporins, or any of the ingredients listed at the end of this leaflet.
    You may have an increased chance of being allergic to IBILEX if you are allergic to penicillins.
  • Some of the symptoms of an allergic reaction may include:
    - shortness of breath, wheezing or difficulty breathing
    - swelling of the face, lips, tongue or other parts of the body
    - rash, itching or hives on the skin.
  • always check the ingredients to make sure you can use this medicine.
  • the expiry date printed on the pack or bottle has passed.
    If you take this medicine after the expiry date, it may not work as well.
  • the package is torn or show signs of tampering, or if the capsules or mixture do not look quite right.

Check with your doctor if you:

  • are allergic to any other medicines or any foods, preservatives or dyes
  • have any other medical conditions, especially the following:
    - liver problems
    - kidney problems
    - bowel problems.
    Your doctor may want to take special care if you have any of these conditions.
  • take any medicines for any other condition.

If you have not told your doctor about any of the above, tell them before you start using IBILEX.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

Your doctor will discuss the risks and benefits of taking IBILEX.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may be affected by IBILEX, or may affect how well it works. These include:

  • probenecid, a medicine commonly used to treat gout
  • metformin, a medicine used to treat diabetes.

Your doctor can tell you what to do if you are taking this medicine.

Talk to your doctor about the need for additional contraception while taking IBILEX.

Some antibiotics may decrease the effectiveness of some birth control pills, although this has not been shown with IBILEX.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect IBILEX.

4. How do I take IBILEX?

How much to take

Follow all directions given to you by your doctor or pharmacist.

They may differ from the information contained in this leaflet.

If you do not understand the instructions on the pack or bottle, ask your doctor or pharmacist.

Adults:

  • Your doctor will tell you how much IBILEX you need to take each day and when to take it.
  • This will depend on the type of infection you have. The dose varied from patient to patient.

Children:

  • The dose for children will depend on the child's age, weight and the type of infection. Your doctor and pharmacist will tell you how much IBILEX your child should take.

When to take IBILEX

  • IBILEX can be taken with or without food.
  • Take IBILEX at about the same time each day, spaced evenly apart.
  • This will allow IBILEX to have its best effect and also help you remember when to take it.

How to take IBILEX

Capsules:

  • Swallow whole with a glass of water.

Suspension:

  • Shake the bottle well then accurately measure the correct dose. Always use a metric measure.

How long to take IBILEX for

  • Keep taking IBILEX until you finish the pack or bottle, or for as long as your doctor recommends.

Do not stop taking IBILEX, even if you feel better, unless advised by your doctor.

Your infection may not clear completely if you stop taking your medicine too soon.

If you forget to use IBILEX

If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.

Otherwise, take the missed dose as soon as you remember, and then go back to taking your medicine as you would normally.

Do not take a double dose to make up for the dose you missed.

If you are not sure what to do, ask your doctor or pharmacist.

If you use too much IBILEX

If you think that you have used too much IBILEX, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (Australia telephone 13 11 26) for advice, or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

If you have taken too much IBILEX, you may feel sick in the stomach, experience diarrhoea, blood in the urine, or have unusually increased reflexes, convulsions or hallucinations.

5. What should I know while using IBILEX?

Things you should do

  • If your symptoms do not improve within a few days, or if they become worse, tell your doctor.
  • If you get severe diarrhoea, tell your doctor or pharmacist immediately. Do this even if it occurs several weeks after you have stopped taking IBILEX. Diarrhoea may mean that you have a serious condition affecting your bowel. You may need urgent medical care. Do not take any diarrhoea medicine without checking with your doctor.
  • If you become pregnant while taking IBILEX, tell your doctor.
  • Before starting any new medicine, tell your doctor or pharmacist that you are taking IBILEX.
  • Tell all the doctors, dentists and pharmacists who are treating you that you are taking IBILEX, especially if you are about to be started on any new medicines.
  • If you have to have any blood or urine tests, tell your doctor that you are taking IBILEX.
    IBILEX may affect the results of some tests.
  • If you are diabetic, check with your doctor or pharmacist before using urine sugar tests.
    IBILEX may affect the results of some of these tests.
  • Keep all of your doctor's appointments so that your progress can be checked.
    Your doctor may do some tests from time to time to make sure the medicine is working and to prevent unwanted side effects.

Remind any doctor, dentist or pharmacist you visit that you are using IBILEX.

Things you should not do

  • Do not stop taking IBILEX or lower the dose because you are feeling better, unless advised by your doctor. If you do not complete the full course prescribed by your doctor, your infection may not clear completely or your symptoms may return.
  • Do not use IBILEX to treat any other conditions unless your doctor tells you to.
  • Do not give IBILEX to anyone else, even if they have the same condition as you.

Things to be careful of

  • If you get a sore, white mouth or tongue while taking or soon after stopping IBILEX, tell your doctor. Also tell your doctor if you get vaginal itching or discharge.
    This may mean you have a fungal infection called thrush. Sometimes, the use of IBILEX allows fungi to grow and the above symptoms to occur. IBILEX does not work against fungi.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how IBILEX affects you.

IBILEX generally does not cause any problems with your ability to drive a car or operate machinery. However, IBILEX may rarely cause dizziness, tiredness or fatigue in some people. If this occurs, do not drive, operate machinery or do anything else that may be dangerous.

Children should be careful when riding bicycles or climbing trees.

Looking after your medicine

  • Keep IBILEX where children cannot reach it.
    A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.
  • Keep your capsules in the pack until it is time to take them.
    If you take your capsules out of the pack, they may not keep as well.
  • Keep your capsules in a cool dry place where the temperature stays below 30°C.
  • Keep IBILEX suspension in the refrigerator but not in the freezer, and keep the bottle tightly closed. Do not use any mixture that is left in the bottle after 14 days.
  • Do not store IBILEX or any other medicine in the bathroom or near a sink.
  • Do not leave IBILEX in the car or on window sills. Heat and dampness can destroy some medicines.

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date.

6.Are there any side effects?

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking IBILEX.

IBILEX treats infections in most people and is usually well tolerated, but it may have unwanted side effects in some people. These side effects are very rare.

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effectsWhat to do
  • sore or white mouth or tongue (oral thrush)
  • sore and itchy vagina and/or discharge (another form of thrush)
  • diarrhoea
  • nausea
  • vomiting
  • dizziness
  • unusual tiredness/weakness
  • abdominal pain
  • headache.
Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
  • fever
  • swelling of the joints
  • yellowing of the skin or eyes
  • joint pain
  • confusion and hallucinations
  • seizure
  • bleeding or bruising more easily than normal.
  • encephalopathy (such as reduced ability to think clearly or concentrate, memory loss, drowsiness, seizures, muscle twitches and personality change)
  • myoclonus (sudden, brief involuntary muscle twitching or jerking)
  • symptoms of an allergic reaction including:
    - rash, itching or hives on the skin
    - swelling of the face, lips, tongue or other parts of the body
    - shortness of breath, wheezing or trouble breathing.
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor immediately if you notice any of the following, even if they occur several weeks after stopping treatment with IBILEX:

  • severe stomach cramps or pain
  • severe, watery or bloody diarrhoea
  • fever, in combination with one of the above.

Do not take any diarrhoea medicine without first checking with your doctor.

You may have a serious condition affecting your bowel requiring urgent medical attention.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What IBILEX contains

Capsules:

Active ingredient
(main ingredient)
cefalexin monohydrate (equivalent to 250 mg or 500 mg of cefalexin)
Other ingredients
(inactive ingredients)
  • Avicel RC 591 (ARTG PI No: 2530)
  • dimeticone 350
  • magnesium stearate
  • gelatin
  • patent blue V
  • quinoline yellow
  • titanium dioxide

Suspension:

Active ingredient
(main ingredient)
cefalexin monohydrate (125 mg/5 mL or 250 mg/5 mL)
Other ingredients
(inactive ingredients)
  • sodium lauryl sulfate
  • allura red AC
  • methylcellulose
  • dimeticone 350
  • xanthan gum
  • pregelatinised maize starch
  • sucrose
  • tuttifrutti 51880 TP0551 (ARTG PI No: 1775)
Potential allergensContains sugars.

Do not take this medicine if you are allergic to any of these ingredients.

What IBILEX looks like

IBILEX is available as capsules or suspension.

Capsule:

The capsules come in two strengths:

  • IBILEX 250 - green and white capsule (AUST R 73524).
  • IBILEX 500 - dark green and light green capsule (AUST R 73525).

Each pack contains 20 capsules.

Suspension:

The suspensions come in two strengths:

  • IBILEX 125 - A white free-flowing powder before reconstitution and a red, fruity bubble gum flavoured suspension after reconstitution (AUST R 92972).
  • IBILEX 250 - A white free-flowing powder before reconstitution and a red, fruity bubble gum flavoured suspension after reconstitution (AUST R 92973).

Each bottle contains 100 mL when reconstituted with water.

Who distributes IBILEX

Alphapharm Pty Ltd trading as Viatris
Level 1, 30 The Bond
30-34 Hickson Road
Millers Point NSW 2000
www.viatris.com.au
Phone: 1800 274 276

This leaflet was prepared in March 2024.

IBILEX® is a Viatris company trade mark

IBILEX_cmi\Mar24/01

Published by MIMS May 2024

BRAND INFORMATION

Brand name

Ibilex

Active ingredient

Cefalexin

Schedule

S4

 

1 Name of Medicine

Cefalexin monohydrate.

2 Qualitative and Quantitative Composition

Each capsule (pulvule) contains cefalexin monohydrate equivalent to 250 mg or 500 mg of cefalexin.
Powder for oral liquid in bottle contains cefalexin monohydrate equivalent to 125 mg or 250 mg of cefalexin per 5 mL upon reconstitution.

Excipient with known effect.

Powder for oral liquid contains sugars.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Ibilex 250 capsules.

An opaque green and white capsule, size 1 containing 250 mg cefalexin.

Ibilex 500 capsules.

An opaque dark green and light green capsule, size 0 containing 500 mg cefalexin.

Ibilex 125 powder for oral liquid.

A white free-flowing powder before reconstitution and a red suspension after reconstitution containing 125 mg cefalexin per 5 mL.

Ibilex 250 powder for oral liquid.

A white free-flowing powder before reconstitution and a red suspension after reconstitution containing 250 mg cefalexin per 5 mL.

4 Clinical Particulars

4.1 Therapeutic Indications

Ibilex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms.
Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic Streptococci. (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefalexin monohydrate is generally effective in the eradication of Streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin monohydrate in the subsequent prevention of rheumatic fever are not available at present.)
Bacterial sinusitis caused by Streptococci, S. pneumoniae and S. aureus (methicillin sensitive only).
Otitis media due to S. pneumoniae, Staphylococci.
Skin and soft tissue infections caused by Staphylococci and/or Streptococci.
Genitourinary tract infections, including acute prostatitis caused by E. coli, P. mirabilis and Klebsiella sp.
The effectiveness of Ibilex in the treatment of bacterial infections of the brain and spinal column has not been established and Ibilex is not indicated in these conditions.

Note.

Appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to Ibilex. Renal function studies should be performed when indicated.

4.2 Dose and Method of Administration

Ibilex is administered orally.

Adults.

The adult dosage ranges from 1 to 4 g daily in divided doses. The usual adult dose is 250 mg every 6 hours.
For streptococcal pharyngitis or tonsillitis, mild, uncomplicated urinary tract infections, and skin and soft tissue infections, a dosage of 500 mg may be administered every 12 hours.
For more severe infections or those caused by less susceptible organisms, larger doses may be needed. If daily doses of Ibilex greater than 4 g are required, parenteral cephalosporins, in appropriate doses, should be considered.
Twice daily dosing is not recommended when doses larger than 1 g daily are administered.

Children.

The usual recommended daily dosage for children is 25 to 50 mg/kg in divided doses. For streptococcal pharyngitis in patients over 1 year of age, tonsillitis, mild, uncomplicated urinary tract infection, and skin and soft tissue infections, the total daily dose may be divided and administered every 12 hours. See Table 1.
In severe infections, the dosage may be doubled.
In the therapy of otitis media, clinical studies have shown that a dosage of 75 to 100 mg/kg/day in 4 divided doses is recommended.
In the treatment of beta-haemolytic streptococcal infections, a therapeutic dosage of Ibilex should be administered for at least 10 days.

4.3 Contraindications

Ibilex is contraindicated in patients with known allergy to the cephalosporin group of antibiotics or who have previously experienced a major allergy to penicillin (see Section 4.4 Special Warnings and Precautions for Use).

4.4 Special Warnings and Precautions for Use

Before instituting therapy with cefalexin monohydrate, every attempt should be made to determine if the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. This product should be given cautiously to penicillin sensitive patients.
There is some clinical and laboratory evidence of partial cross allergenicity of the penicillins and the cephalosporins. Patients have been reported to have had severe reactions (including anaphylaxis) to both drugs.
If an allergic reaction to Ibilex occurs, the drug should be discontinued and the patient treated with the usual agents (e.g. adrenaline (epinephrine) or other pressor amines, antihistamines or corticosteroids).
Antibiotic associated pseudomembranous colitis has been reported with virtually all broad spectrum antibiotics (including macrolides, semisynthetic penicillins and cephalosporins). A toxin produced with Clostridium difficile appears to be the primary cause. The severity of the colitis may range from mild to life threatening. It is important to consider this diagnosis in patients who develop diarrhoea or colitis in association with antibiotic use (this may occur up to several weeks after cessation of antibiotic therapy). Mild cases usually respond to drug discontinuation alone. However, in moderate to severe cases, appropriate therapy with a suitable oral antibacterial agent effective against Clostridium difficile should be considered. Fluids, electrolytes and protein replacement should be provided when indicated.
Drugs which delay peristalsis, e.g. opiates and diphenoxylate with atropine (Lomotil) may prolong and/or worsen the condition and should not be used.
Broad spectrum antibiotics should therefore be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Patients should be followed carefully so that any side effects or unusual manifestations of drug idiosyncrasy may be detected.
Prolonged use of Ibilex may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Neurotoxicity.

There have been reports of neurotoxicity associated with cephalosporin treatment. Symptoms of neurotoxicity include encephalopathy, seizures and/or myoclonus. Risk factors for developing neurotoxicity with cephalosporin treatment include being elderly, renal impairment, central nervous system disorders and intravenous administration. Withdrawal of the medicine should be considered if there are signs of neurotoxicity. Anticonvulsant therapy can be given if clinically indicated.

Use in renal impairment.

Ibilex should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended.
Indicated surgical procedures should be performed in conjunction with antibiotic therapy.

Use in the elderly.

No data available.

Paediatric use.

No data available.

Severe cutaneous adverse reactions.

Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP) have been reported in patients taking beta-lactam antibiotics. When SCAR is suspected, Ibilex should be discontinued immediately and an alternative treatment should be considered.

Effects on laboratory tests.

The quantitative determination of urinary protein excretion using strong acids is misleading during Ibilex therapy as precipitation of cefalexin monohydrate in the urine may occur.
A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solution or with Clinitest.
Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematologic studies, or in transfusion cross matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.

4.5 Interactions with Other Medicines and Other Forms of Interactions

As with other β-lactams, the renal excretion of Ibilex is inhibited by probenecid.
In healthy subjects given single 500 mg doses of cefalexin monohydrate and metformin, plasma metformin Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin renal clearance decreased by an average of 14%. The interaction of cefalexin monohydrate and metformin following multiple dose administration has not been studied. Administration of a cephalosporin to a metformin treated patient may result in increased metformin exposure.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
(Category A)
Cefalexin monohydrate is excreted in the milk. Caution should be exercised when Ibilex is administered to a nursing woman. Alternative feeding arrangements for the infant should be considered.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Adverse drug reactions reported with cefalexin monohydrate are very rare (< 0.01%) and are listed below.

Blood and lymphatic system disorders.

Eosinophilia, neutropenia, thrombocytopenia, haemolytic anaemia.

Gastrointestinal disorders.

Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain.

General disorders and administration site conditions.

Fatigue.

Hepatobiliary disorders.

Cholestatic jaundice, transient hepatitis, elevated SGOT, elevated SGPT.

Immune system disorders.

Allergic reactions, urticaria, angioedema.
These reactions usually subsided upon discontinuation of the drug.
Anaphylaxis has also been reported.

Infections and infestations.

Pseudomembranous colitis.

Musculoskeletal and connective tissue disorders.

Joint disorder, arthralgia, arthritis.

Nervous system disorders.

Dizziness, headache, seizure.
Encephalopathy, myoclonus (frequency not known).

Psychiatric disorders.

Hallucinations, agitation, confusion.

Renal and urinary disorders.

Reversible interstitial nephritis.

Reproductive and breast disorders.

Genital and anal pruritus, genital moniliasis, vaginitis, vaginal discharge.

Skin and subcutaneous tissue disorders.

Rash, erythema multiforme.
These reactions usually subsided upon discontinuation of the drug.
Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP) have been reported in beta-lactam antibiotics.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

There is no definite experience of poisoning or severe overdosage with cefalexin monohydrate. However, clinical features of overdosage may be similar to those seen with other cephalosporins and penicillins, i.e. convulsions, hallucinations, hyper-reflexia, electrolyte imbalance, gastrointestinal disturbances and haematuria.
In the event of severe overdosage, general supportive care is recommended, including close clinical and laboratory monitoring of haematological, renal, hepatic functions and coagulation status until the patient is stable.
Forced diuresis, peritoneal dialysis, haemodialysis or charcoal haemoperfusion have not been established as beneficial for an overdose of cefalexin monohydrate.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

In vitro tests demonstrate that the cephalosporins are bactericidal because of their inhibition of cell wall synthesis. Ibilex is active against the following organisms in vitro: Beta-haemolytic Streptococci, Staphylococci (including coagulase positive, coagulase negative and penicillinase producing strains), Streptococcus (Diplococcus) pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella sp.

Note.

Most strains of Enterococci (Enterococcus faecalis) and a few strains of Staphylococci are resistant to Ibilex. It is not active against most strains of Enterobacter sp., Morganella morganii (formerly Proteus morganii) and Proteus vulgaris. It has no activity against Pseudomonas or Acinetobacter calcoaceticus (formerly Mima and Herellea sp.). When tested by in vitro methods, Staphylococci exhibit cross resistance between cefalexin monohydrate and methicillin type antibiotics.
Disc susceptibility tests. Dilution or diffusion techniques, either quantitative (MIC) or breakpoint, should be used following a regularly updated, recognised and standardised method (e.g. NCCLS). Standardised susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.
A report of "susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "intermediate" indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone, which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Note.

The prevalence of resistance may vary geographically for selected species and local information on resistance is desirable, particularly when treating severe infections.
Minimal inhibitory concentration (MIC) breakpoints. Zone diameters, reported off cephalothin discs, are provided with corresponding breakpoints. See Table 2.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption.

Ibilex is acid stable and may be given without regard to meals.
It is rapidly absorbed after oral administration.
Following doses of 250 mg, 500 mg, and 1 g, average peak serum levels of approximately 9, 18, and 32 microgram/mL, respectively, were obtained at 1 hour. Measurable levels were present 6 hours after administration.

Excretion.

Cefalexin monohydrate is excreted in the urine by glomerular filtration and tubular secretion. Studies showed that over 90% of the drug was excreted unchanged in the urine within 8 hours. During this period, peak urine concentrations following the 250 mg, 500 mg, and 1 g doses were approximately 1000, 2200, and 5000 microgram/mL, respectively.

5.3 Preclinical Safety Data

Genotoxicity.

No data available.

Carcinogenicity.

No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Each capsule (pulvule) contains Avicel RC 591 (ARTG PI No: 2530), dimeticone 350, magnesium stearate, patent blue V, quinoline yellow, titanium dioxide and gelatin.
Powder for oral liquid in bottle contains sodium lauryl sulfate, allura red AC, methylcellulose, dimeticone 350, xanthan gum, pregelatinised starch, Tuttifrutti 51880 TP0551 (ARTG PI No: 1775) and sucrose.

6.2 Incompatibilities

See Section 4.5 Interactions with Other Medicines and Other Forms of Interactions.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Ibilex capsules.

Ibilex 250 mg and 500 mg: Store below 30 degrees Celsius.

Ibilex powder for oral liquid.

Store below 25 degrees Celsius and protect from light. Upon reconstitution, the suspension must be stored in a refrigerator between 2 and 8 degrees Celsius. Do not freeze. Discard unused portion 14 days after mixing.

6.5 Nature and Contents of Container

Ibilex 250 and 500 capsules: PVC/Al blister pack of 20.
Ibilex 125 and 250 Powder for oral liquid: HDPE bottle of 100 mL.

Australian register of therapeutic goods (ARTG).

AUST R 73524 - Ibilex 250 cefalexin 250 mg capsule blister pack.
AUST R 73525 - Ibilex 500 cefalexin 500 mg capsule blister pack.
AUST R 92972 - Ibilex 125 cefalexin 125 mg/5 mL powder for oral liquid bottle.
AUST R 92973 - Ibilex 250 cefalexin 250 mg/5 mL powder for oral liquid bottle.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy.

6.7 Physicochemical Properties

Chemical structure.

Chemical name: 7-(D-α-amino-α-phenyl-acetamido)-3-methyl-3-cephem-4-carboxylic acid, monohydrate.
Structural:
Molecular formula: C16H17N3O4S.H2O. Molecular weight: 365.41.

CAS number.

23325-78-2.
The nucleus of cefalexin monohydrate is related to that of other cephalosporin antibiotics. The compound is a zwitterion (i.e. the molecule contains both a basic and an acidic group). The isoelectric point of cefalexin monohydrate in water is approximately 4.5 to 5.
The crystalline form of cefalexin which is available is a monohydrate. It is a white crystalline solid having a bitter taste. Solubility in water is low at room temperature; 1 or 2 mg/mL may be dissolved readily, but higher concentrations are obtained with increasing difficulty.
The cephalosporins differ from penicillins in the structure of the bicyclic ring system. Cefalexin monohydrate has a D-phenylglycyl group as substituent at the 7-amino position and an unsubstituted methyl group at the 3-position.

7 Medicine Schedule (Poisons Standard)

S4 (Prescription Only Medicine).

Summary Table of Changes